The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment.
Saved in:
| Title: | The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment. |
|---|---|
| Authors: | Mirzaei R; Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Azimi M; Department of Biochemistry, Medical Faculty, Saveh Branch, Islamic Azad University, Saveh, Iran., Karimi S; Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran., Karimi MS; Department of Anesthesiology, Pain, and Critical care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran., Aghel SAM; Department of Molecular and Translational Medicine, Nocivelli Institute for Molecular Medicine, University of Brescia, Brescia, Italy., Salehi M; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Jalili N; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Yadegari F; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Farahmand L; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. laylafarahmand@gmail.com. |
| Source: | Investigational new drugs [Invest New Drugs] 2025 Jun; Vol. 43 (3), pp. 687-700. Date of Electronic Publication: 2025 May 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
